Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

AADAPT - Analysis of Advagraf Dose Adaptation Post Transplantation (AADAPT)

This study has been completed.
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Nice Identifier:
First received: September 15, 2011
Last updated: July 28, 2014
Last verified: August 2011

A pharmacokinetics and pharmacogenetics study to complement the current knowledge of tacrolimus prolonged release (Advagraf®) in the immediate post-transplantation period and at steady-state (M3 post transplantation) and to improve the optimal dose of Advagraf® based on tacrolimus AUC estimated by two Limited Samples Strategies during the first 3 months after renal transplantation.

Data obtained with tacrolimus prolonged release will be compared with those of tacrolimus immediate release (Prograf®)

Condition Intervention Phase
Renal Transplantation
Drug: Advagraf Capsule
Drug: Prograf Capsule
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Prospective Pharmacokinetic and Pharmacogenetic Analysis of Advagraf After Transplantation

Resource links provided by NLM:

Further study details as provided by Centre Hospitalier Universitaire de Nice:

Primary Outcome Measures:
  • AUC 0-24h of tacrolimus at Day 8 and Day 84 [ Time Frame: 3 months ]

Secondary Outcome Measures:
  • AUC 24h of tacrolimus using limited samples strategies (LSS) at Day 8 and Day 84 [ Time Frame: 3 months ]

Enrollment: 45
Study Start Date: October 2011
Study Completion Date: July 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Advagraf Drug: Advagraf Capsule

Other Names:

  • FK506E
  • MR4
  • tacrolimus modified/prolonged release Drug: MPA Solution for infusion and per os Other Name: Mycophenolate Mofetil or Mycophenolic Acid Drug: Basiliximab IV infusion Other Name: Simulect Drug: Corticosteroids per os Other Name: Methylprednisolone or equivalent
Active Comparator: Prograf Drug: Prograf Capsule

Other Names:

  • FK506E
  • MR4
  • tacrolimus Drug: MPA Solution for infusion and per os Other Name: Mycophenolate Mofetil or Mycophenolic Acid Drug: Basiliximab IV infusion Other Name: Simulect Drug: Corticosteroids per os Other Name: Methylprednisolone or equivalent

Detailed Description:

Multicentre open-labeled randomized pharmacokinetic (PK) and pharmacogenetic (PG) study to compare Advagraf and Prograf immediate post-transplantation (Day 8) and steady-state (Day 84) systemic exposure.

Tacrolimus PK profile, tacrolimus systemic exposure assessed by Limited Samples Strategies (LSS) (i.e.: Bayesian estimators (BE) and Multilinear Regressions (MLR)), and impact of CYP3A5 and ABCB1 genetic polymorphisms on tacrolimus PK will also be determined to improve the optimal dose of Advagraf® for kidney transplant patients.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult recipients aged between 18 to 70
  • Primary renal transplantation
  • Cadaver or living transplantation or living (non HLA identical) donor with compatible ABO blood type.
  • absence of anti-LHA antibodies in lymphocytotoxicity and Luminex
  • Negative cross-match in cytotoxicity
  • Negative pregnancy test for female patients of childbearing potential, and agreement to practice effective birth control during the study

Exclusion Criteria:

  • Combined transplantation
  • Renal bigraft
  • History of any other transplantation
  • Receiving a graft from a non-heart-beating donor.
  • Requiring ongoing dosing with a systemic immunosuppressive drug prior to transplantation
  • Patient who received within one month prior to study an inductor of CYP50 3A or requiring during the study an inhibitor of CYP50 3A or of P-gp.
  • Significant, uncontrolled concomitant infections and/or severe diarrhoea, vomiting, active upper gastro-intestinal tract malabsorption or active peptic ulcer
  • Subject or donor known to be HIV positive
  • Active viral hepatitis (VHB, VHC) at randomisation
  • Known allergy or intolerance to tacrolimus, macrolide antibiotics, corticosteroids, or mycophenolate mofetil or any of the product excipients
  • Diagnosis of new-onset malignancy prior to transplantation, with the exception of basocellular or squamous cell carcinoma of the skin which had been treated successfully.
  • Current participation in any other clinical study
  • Any clinical condition which, in the opinion of the investigator, would not allow safe completion of the study
  • Patient not able to comply with the study procedures
  • Breast-feeding mother
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01435291

Hôpital Bicêtre
Kremlin Bicêtre, France
CHU de Nice
Nice, France, 06200
CHU de Rangueil
Toulouse, France
CHRU Tours Hôpital Bretonneau
Tours, France
Sponsors and Collaborators
Centre Hospitalier Universitaire de Nice
Principal Investigator: Elisabeth CASSUTO, PH CHU de Nice
  More Information

Responsible Party: Centre Hospitalier Universitaire de Nice Identifier: NCT01435291     History of Changes
Other Study ID Numbers: 11-PP-07
Study First Received: September 15, 2011
Last Updated: July 28, 2014

Additional relevant MeSH terms:
Mycophenolic Acid
Mycophenolate mofetil
Antibiotics, Antineoplastic
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Neuroprotective Agents
Protective Agents
Immunosuppressive Agents
Immunologic Factors
Calcineurin Inhibitors processed this record on April 28, 2017